scholarly journals The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy

2016 ◽  
Vol 5 ◽  
pp. 386-390
Author(s):  
Michelle I. Echevarria ◽  
Arash O. Naghavi ◽  
Puja S. Venkat ◽  
Yazan A. Abuodeh ◽  
Carlos Chevere ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Dose Rate ◽  
Body Mass ◽  
Low Dose ◽  
Prostate Brachytherapy ◽  
Low Dose Rate ◽  
The Impact

scholarly journals MP72-18 BODY MASS INDEX AND ANTERIOR PERIRECTAL FAT THICKNESS IS A PREDICTOR OF RECTAL COMPLICATION AFTER LOW DOSE RATE PROSTATE BRACHYTHERAPY

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Young Dong Yu* ◽  
Tae Heon Kim ◽  
Seung Ryeol Lee ◽  
Young Kwon Hong ◽  
Dong Soo Park
Keyword(s):  
Body Mass Index ◽  
Dose Rate ◽  
Body Mass ◽  
Low Dose ◽  
Prostate Brachytherapy ◽  
Low Dose Rate ◽  
Fat Thickness

Preliminary results of a study on focal low dose rate prostate brachytherapy using Cesium 131.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 151-151
Author(s):  
Brian Joseph Moran ◽  
Michelle H. Braccioforte
Keyword(s):  
Prostate Cancer ◽  
Dose Rate ◽  
Low Dose ◽  
Prostate Volume ◽  
Focal Therapy ◽  
Long Term Results ◽  
Prostate Brachytherapy ◽  
Psa Kinetics ◽  
Low Dose Rate ◽  
The Impact

151 Background: Prostate cancer patients continue to seek out minimally invasive therapies with equal disease eradication, but with less morbidity, lower cost and multiple salvage options. Our objective was to evaluate PSA response and determine rate of prostate specific antigen (PSA) kinetics in patients undergoing permanent low dose rate (LDR) focal prostate brachytherapy at a single institution. Methods: Between 4/2015 – 1/2017, 52 patients, of which 25% of patients were diagnosed with prostate cancer using a stereotactic transperineal mapping biopsy approach, while 75% had a standard transrectal prostate biopsy, were treated with LDR focal prostate brachytherapy. Dose to target was 115 Gy using Cesium-131. 30 patients (57.7%) were considered low risk, 21 pts (40.4%) were intermediate, and 1 patient (1.9%) was high risk. Treatment was limited to the side of the gland where the cancer was diagnosed. Because there is no agreed upon standard regarding PSA control, we are choosing to call the percent change in PSA the “Impact PSA”. Results: Median pre-treatment prostate volume was 51.6 cm3 (range 18 – 129 cm3), while the median target volume was 17.8 cm3 (range 7.6 – 39.4 cm3). Additionally, the median prostate volume treated was 33.73% (range 17.6 – 95.3%). Our data demonstrates that patients in whom 25-50% of the gland treated, resulted in an Impact PSA of approximately 25% - 50% decrease in total PSA between 3 - 6 months, with continued decreases of 55% at 1 year, and 77% at 2 years. Conclusions: Focal therapy outcomes are highly variable and related to volume of ablation. For low volume disease, LDR focal brachytherapy may be a viable option for patients. Optimal outcome assessment after focal therapy is yet to be determined. Since there is untreated gland with the potential to produce PSA, perhaps stable patterns in PSA kinetics, rather than a nadir, is more valuable. We will continue to follow-up with this cohort to report long term results and closely study the Impact PSA.

scholarly journals The Impact of BMI on Dosimetric Quality in Low Dose Rate Prostate Brachytherapy

Brachytherapy ◽  
2016 ◽  
Vol 15 ◽  
pp. S192-S193
Author(s):  
Michelle I. Echevarria ◽  
Arash O. Naghavi ◽  
Yazan A. Abuodeh ◽  
Carlos M. Chevere ◽  
Kosj Yamoah
Keyword(s):  
Dose Rate ◽  
Low Dose ◽  
Prostate Brachytherapy ◽  
Low Dose Rate ◽  
The Impact

Hemi-gland focal low dose rate prostate brachytherapy: An analysis of dosimetric outcomes

2016 ◽  
Vol 121 (2) ◽  
pp. 310-315 ◽  
Author(s):  
Robert Laing ◽  
Adrian Franklin ◽  
Jennifer Uribe ◽  
Alex Horton ◽  
Santiago Uribe-Lewis ◽  
...  
Keyword(s):  
Dose Rate ◽  
Low Dose ◽  
Prostate Brachytherapy ◽  
Low Dose Rate
Sign in / Sign up

Export Citation Format

Share Document